Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1398 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-02-29

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the ADDUCE project is to investigate any adverse effects of methylphenidate (trade name ritalin) on growth, neurological system, psychiatric states and cardiovascular system over a two year period in children and adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants

NCT01310439

Attention Deficit Hyperactivity Disorder

COMPLETED

Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)

NCT01740206

Attention Deficit Hyperactivity Disorder

COMPLETED NA

Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder

NCT00223561

ADHD

COMPLETED PHASE4

Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD

NCT02074228

Attention-deficit/Hyperactivity Disorder

UNKNOWN PHASE4

Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions

NCT00372359

Attention Deficit Disorder With Hyperactivity Attention Deficit Disorder Attention Deficit Hyperactivity Disorder +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH, trade name ritalin) is the most-commonly prescribed medication for ADHD children; it is also increasingly used in ADHD adults. In 2007, the European Commission requested a referral to the Committee for Medicinal Products for Human Use (CHMP) under Article 31 of Directive 2001/83/EC, as amended, for MPH because of safety concerns. The CHMP concluded that study of the long-term effects of MPH on growth, sexual development, neurological system, psychiatric states and cardiovascular system is needed. In response to the CHMP s concerns, the ADDUCE (Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects) research team has been formed by a consortium of experts in the fields of ADHD, drug safety, neuro-psychopharmacology and cardiovascular research.

The ADDUCE project aims to investigate the long-term adverse effects of MPH on growth, neurological system, psychiatric states and cardiovascular system in children and adults.

Furthermore the ADDUCE team will develop research tools for the evaluation of adverse effects of MPH on cognition and motivation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder (ADHD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADHD medicated

Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.

No interventions assigned to this group

ADHD unmedicated controls

Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate

No interventions assigned to this group

Non-ADHD controls

Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (\<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

ADHD-treated group:

* Clinical diagnosis of ADHD
* Aged between 5 and 17 years.
* Not previously treated with methylphenidate
* Agreement between clinician, patient and their family to commence on methylphenidate (baseline measures will be taken before first prescription of methylphenidate is issued).
* Any co-medication other than dexamfetamine or atomoxetine will be allowed.
* All psychiatric and physical illness comorbidities will be allowed

ADHD-unmedicated controls:

* Clinical diagnosis of ADHD not previously treated with medication.
* Aged between 5 and 17 years.
* Agreement between clinician, patient and their family not to treat with methylphenidate.
* Any medication other than dexamfetamine or atomoxetine will be allowed.
* All comorbidities will be allowed.

Non-ADHD controls:

* Child who does not have ADHD.
* Aged between 5 and 17 years.
* Mean total clinician rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) score (ADHD items) \< 1.5
* Parent rated Strengths and Difficulties Questionnaire (SDQ) Hyperactivity Score within normal range for country (e.g. \< 6 for UK)
* Any current medication other than dexamfetamine or atomoxetine will be allowed.
* Must never have taken methylphenidate
* Any other mental health or physical illness diagnoses will be allowed.

Exclusion Criteria

All Groups:

* Current or past treatment with dexamfetamine or atomoxetine.

Un-medicated ADHD controls:

* Previous or current treatment with methylphenidate.

Non-ADHD controls:

* Previous or current treatment with methylphenidate.
* Clinician rated SNAP score ≥ 1.5. Parent rated SDQ Hyperactivity Score in Borderline or Abnormal range.

Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes